KRAZATI

Adagrasib 200mg, Oral tablet

Cannabis

· Severity: Major

· Notes for Consumers: Discuss cannabis use with your care team. The effects of cannabis may be altered if used with your medication. Call emergency services right away if you experience slow or shallow breathing, shortness of breath, feeling faint, dizziness, confusion, or trouble staying awake.

· Notes for Professionals: Advise patients to avoid cannabis use during adagrasib treatment. Concomitant use may alter the exposure of some cannabinoids and increase the risk for adverse reactions. The cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are CYP3A and CYP2C9 substrates and adagrasib is a strong CYP3A and moderate CYP2C9 inhibitor. Concomitant use of a cannabinoid product containing THC and CBD at an approximate 1:1 ratio with another strong CYP3A inhibitor increased THC, 11-OH-THC, and CBD peak exposure by 1.3-, 3-, and 1.9-fold respectively.

Adagrasib 200mg, Oral tablet

Grapefruit juice

· Severity: Major

· Notes for Consumers: Do not drink grapefruit juice or eat grapefruit while taking this medication. Grapefruit may alter the effects of your medication. Serious side effects may occur. Contact your care team right away if you experience new or worsening side effects.

· Notes for Professionals: Advise patients to avoid grapefruit and grapefruit juice during adagrasib treatment due to the risk of increased adagrasib exposure and adverse reactions. Adagrasib is a CYP3A substrate and grapefruit juice is a strong CYP3A inhibitor.

<b>DISCLAIMER:</b><em> This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment. Drug information is sourced from GSDD (Gold Standard Drug Database ) provided by Elsevier.</em>